NCT00088192已完成不适用
An Open Label, Non-Comparative Protocol for Use of Intravitreous Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration (AMD)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 40
研究概览
简要总结
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until such time as the patient's lesion is considered to have resolved or stabilized in the opinion of the treating ophthalmologist, or product becomes commercially available.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Best corrected visual acuity in the study eye between 20/40 and 20/
- •Subfoveal choroidal neovascularization, secondary to age related macular degeneration, with a total lesion size [including blood, scar/atrophy & neovascularization] of < 12 total disc areas, of which at least 50% must be active CNV.
- •Any subretinal hemorrhage must comprise no more than 50% of total lesion size.
- •General Criteria:
- •Patients of either gender, aged greater than 50 years.
- •Women must be using two forms of effective contraception, or be post-menopausal for at least 12 months prior to study entry, or surgically sterile. If of child-bearing potential, a serum pregnancy test must be performed within 48 hours prior to treatment and the result made available prior to treatment initiation. The two forms of effective contraception must be implemented during the study and for at least 60 days following the last dose of test medication.
- •Written informed consent.
排除标准
- •Any subfoveal scarring or atrophy and no more than 25% of the total lesion size may be made up of scarring or atrophy.
- •Patients who are eligible for PDT with Visudyne
- •Patients who are eligible for any other of the Sponsor's ongoing AMD studies still open to enrollment.
研究者
研究点 (40)
Loading locations...
相似试验
撤回
不适用
Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic MyopiaMyopic Choroidal Neovascular MembraneNCT01218230L.V. Prasad Eye Institute
尚未招募
不适用
To study the safety and efficacy of Pegaptanib eye injection in the treatment of retinal bleeding due to myopiaCTRI/2011/07/001919VPrasad Eye Institute20
进行中（未招募）
不适用
Treatment of a chorioretinal disease characterized by alterations in the elastic lamina of the Bruch's membrane, and which typically manifest themselves as streaks radial departure from the optic nerveEUCTR2014-000986-30-ITIRCCS Ospedale San Raffaele U.O. Oculistica
已完成
4 期
Bevacizumab Intravitreal for Myopic Choroidal NeovascularizationMyopic Choroidal NeovascularizationNCT00797992Instituto de Olhos de Goiania5
进行中（未招募）
1 期
Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) - PXE-CNV 06Pseudoxanthoma elasticum (PXE) is an inherited systemic disease characterized by changes in the elastic tissue. Pseudoxanthoma elasticum mainly affects the skin, eyes, heart, and GI system. The cutaneous and ocular findings of PXE are referred to as Grönblad-Strandberg syndrome. Pseudoxanthoma elasticum may be autosomal dominant or autosomal recessive. In Pseudoxanthoma elasticum, choroidal nevoscualrization (CNV) is a frequently occuring complication in late stage diseaseMedDRA version: 8.1Level: LLTClassification code 10037150Term: Pseudoxanthoma elasticumEUCTR2006-006231-49-DEDepartment of Ophthalmology, Bonn University10